Linc00152在脑胶质瘤中的表达及其与患者临床预后的关系

目的研究Linc00152在脑胶质瘤中的表达及其与患者临床预后的关系。方法分别检测linc00152在胶质瘤细胞系与肿瘤组织中的表达,分析其与临床病理特征及预后的关系,初步探讨linc00152在脑胶质瘤中的功能。结果与癌旁脑组织(n=73)相比,在胶质瘤组织(n=73)中Linc00152的表达显著上调(P0.001);Linc00152高表达与肿瘤的高级别临床分级显著相关(P0.05);Kaplan-Meier分析显示Linc00152低表达患者总生存期显著高于高表达者(p0.001);Cox回归分析显示,Linc00152表达与临床病理分级是胶质瘤患者预后的独立危险因素(P0.05)。结论 Linc00152在脑胶质瘤组织和细胞系中表达显著上调,Linc00152的高表达提示脑胶质瘤患者预后较差,是候选脑胶质瘤预后检测分子标志物及治疗的潜在分子靶点。

Expression of Linc00152 in glioma and its association with prognosis

Objective To investigate the expression of Linc00152 in glioma and its association with prognosis.Methods The expression of Linc00152 in glioma cell line and glioma tissue was measured, and its association with clinicopathological features and prognosis was analyzed to investigate the function of Linc00152 in glioma.Results Compared with the adjacent brain tissue (73 samples), the glioma tissue (73 samples) had significantly up-regulated expression of Linc00152 (P<0.001). High expression of Linc00152 was significantly associated with advanced clinical classification of glioma (P<0.05). The Kaplan-Meier analysis showed that patients with low expression of Linc00152 had significantly longer overall survival than those with high expression of Linc00152 (P<0.001). The Cox regression analysis showed that expression of Linc00152 and clinicopathological grade were independent risk factors for the prognosis of glioma patients (P<0.05).Conclusions The expression of Linc00152 is significantly up-regulated in glioma tissue and cell lines, and high expression of Linc00152 suggests poor prognosis of glioma patients. Therefore, Linc00152 can be used as a candidate molecular maker for the prognosis of glioma and a potential molecular target for treatment.